# Bausch & Lomb Incorporated clinical trials: 223 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 223 trials with Bausch & Lomb Incorporated as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Bausch & Lomb Incorporated: 223 rows for $11.15, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/bausch-and-lomb-incorporated

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 223
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 223, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 21, 2026 | NCT07778888 | BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial | Bausch & Lomb Incorporated | Phase 2 | Recruiting | Dry Eye Disease | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778888) |
| July 21, 2026 | NCT07717918 | A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants | Bausch & Lomb Incorporated | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717918) |
| February 17, 2026 | NCT07412496 | A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy | Bausch & Lomb Incorporated | Phase 2 | Completed | Pain, Postoperative | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412496) |
| January 30, 2026 | NCT07377474 | A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis... | Bausch & Lomb Incorporated | Not applicable | Not yet recruiting | Myopic Astigmatism | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07377474) |
| September 11, 2025 | NCT07168902 | Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension | Bausch & Lomb Incorporated | Phase 2 | Completed | Glaucoma | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168902) |
| August 19, 2025 | NCT07128628 | A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease | Bausch & Lomb Incorporated | Phase 2 | Completed | Dry Eye Disease | 443 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128628) |
| August 8, 2025 | NCT07111013 | A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease | Bausch & Lomb Incorporated | Phase 3 | Withdrawn | Dry Eye Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07111013) |
| July 8, 2025 | NCT07054606 | A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear | Bausch & Lomb Incorporated | Phase 4 | Completed | Dry Eye | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07054606) |
| May 18, 2025 | NCT06978244 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers | Bausch & Lomb Incorporated | Phase 1 | Active not recruiting | Ocular Pain | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06978244) |
| January 31, 2025 | NCT06803654 | A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in... | Bausch & Lomb Incorporated | Phase 3 | Completed | Ocular Redness | 578 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06803654) |
| January 21, 2025 | NCT06785194 | Revive Toric RWE Study | Bausch & Lomb Incorporated | Observational | Withdrawn | Astigmatism | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06785194) |
| October 1, 2024 | NCT06618547 | Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial... | Bausch & Lomb Incorporated | Not applicable | Not yet recruiting | Myopia | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06618547) |
| September 19, 2024 | NCT06594185 | A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract... | Bausch & Lomb Incorporated | Not applicable | Completed | Cataract | 335 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06594185) |
| August 22, 2024 | NCT06565650 | A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo®... | Bausch & Lomb Incorporated | Phase 4 | Active not recruiting | Dry Eye | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06565650) |
| June 28, 2024 | NCT06479148 | Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens | Bausch & Lomb Incorporated | Not applicable | Terminated | Cataract | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06479148) |
| April 4, 2024 | NCT06346340 | A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy | Bausch & Lomb Incorporated | Phase 4 | Completed | Dry Eye | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06346340) |
| March 27, 2024 | NCT06333028 | A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction | Bausch & Lomb Incorporated | Observational | Completed | Cataract | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06333028) |
| March 27, 2024 | NCT06333015 | Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction | Bausch & Lomb Incorporated | Not applicable | Completed | Cataract | 304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06333015) |
| March 13, 2024 | NCT06309953 | A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease | Bausch & Lomb Incorporated | Phase 4 | Completed | Dry Eye | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06309953) |
| March 12, 2024 | NCT06305663 | A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the... | Bausch & Lomb Incorporated | Not applicable | Recruiting | Myopia | 418 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06305663) |
| October 25, 2023 | NCT06098937 | Kalifilcon A Toric Compared to Commercially Available Lenses | Bausch & Lomb Incorporated | Not applicable | Completed | Astigmatism | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06098937) |
| October 6, 2023 | NCT06069609 | Orientation Characteristics of Daily Disposable Toric Contact Lenses | Bausch & Lomb Incorporated | Not applicable | Completed | Astigmatism | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06069609) |
| September 29, 2023 | NCT06060041 | IC-8 Apthera IOL New Enrollment Post Approval Study | Bausch & Lomb Incorporated | Observational | Recruiting | Cataract, Presbyopia, Posterior Capsule Opacification | 435 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06060041) |
| September 26, 2023 | NCT06053736 | 1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses | Bausch & Lomb Incorporated | Not applicable | Completed | Refractive Ametropia, Astigmatism | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06053736) |
| August 9, 2023 | NCT05984290 | Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in the Arise Orthokeratology Lens | Bausch & Lomb Incorporated | Not applicable | Completed | Myopia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05984290) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 4 |
| Phase 2 | 28 |
| Phase 2/3 | 7 |
| Phase 3 | 55 |
| Phase 4 | 23 |
| Not applicable | 83 |
| Observational | 9 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 199 |
| Terminated | 11 |
| Withdrawn | 6 |
| Recruiting | 3 |
| Active not recruiting | 2 |
| Not yet recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Cataract | 37 |
| Myopia | 35 |
| Dry Eye Syndromes | 23 |
| Astigmatism | 19 |
| Inflammation | 16 |
| Conjunctivitis, Allergic | 15 |
| Pain | 12 |
| Ocular Hypertension | 10 |
| Conjunctivitis, Bacterial | 6 |
| Glaucoma, Open-Angle | 6 |
| Presbyopia | 6 |
| Glaucoma | 4 |
| Rhinitis, Allergic, Seasonal | 4 |
| Hyperemia | 3 |
| Diabetic Retinopathy | 3 |
| Refractive Errors | 3 |
| Aphakia | 3 |
| Conjunctivitis | 3 |
| Hyperopia | 3 |
| Vitreous Hemorrhage | 2 |
| Vision Disorders | 2 |
| Eye Diseases | 2 |
| Drug Hypersensitivity | 2 |
| Postoperative Complications | 2 |
| Vitreous Detachment | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
- [Business banking companies in the United States](https://specstream.ai/data/businesses/business-banking-companies/united-states)
- [Eye care clinics in the United States](https://specstream.ai/data/businesses/eye-care-clinics/united-states)
- [Law firms in the United States](https://specstream.ai/data/businesses/law-firms/united-states)
- [Promotional products companies in the United States](https://specstream.ai/data/businesses/promotional-products-companies/united-states)
- [Vegetarian restaurants in the United States](https://specstream.ai/data/businesses/vegetarian-restaurants/united-states)
